Protocol for Wegovy for Reduction of Major Adverse Cardiovascular Events (MACE)

Approved July 2024

Criteria for approval:

1. Patient is of the FDA labeled age for this indication
2. Patient has established cardiovascular disease as evidenced by at least ONE of the following:
   a. Prior myocardial infarction
   b. Prior ischemic or hemorrhagic stroke
   c. Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) less than 0.85 (at rest), peripheral arterial revascularization procedure, or amputation
   d. Positive nuclear stress test
   e. Ischemic cardiomyopathy
   f. History of revascularization (coronary artery bypass grafting, percutaneous coronary intervention, or angioplasty)
3. Documentation that patient has a body mass index (BMI) ≥27
4. Medication is prescribed by or in consultation with a cardiologist or vascular specialist
5. Medication will be used with caution in patients with type 1 diabetes mellitus.
6. Patient does not have any contraindications for use of Wegovy
7. Patient will not be utilizing another GLP-1 receptor agonist concomitantly
8. Documentation that member has received individualized healthy lifestyle counseling
9. Prescriber will maintain the patient on appropriate cardiovascular pharmacotherapy for their cardiovascular disease
10. Patient's target dose will be in the range of manufacturer dosing shown to reduce major cardiovascular events as tolerated

Continuation of therapy:

1. Patient has attained and is tolerating the maintenance dose of 2.4mg weekly, or documentation is provided justifying the use of a different dose
2. There is no documented evidence of worsening cardiovascular health attributable to Wegovy
3. Patient remains on appropriate cardiovascular pharmacotherapy for their cardiovascular disease.

NOTE: Wegovy has a black box warning regarding thyroid C-cell tumors. Please see full prescribing information for details.

Approval Duration and Quantity Restrictions:

- Initial Approval: 7 months
- Renewal Approval: 12 months

Quantity Level Limit:

Drug	Dosage	1 Month Limit
Wegovy (semaglutide)	0.25 mg/0.5 mL	2 mL (1 package of 4 pens each) / 30 days
	0.5 mg/0.5 mL	
	1 mg/0.5 mL	
	1.7 mg/0.75 mL	3 mL (1 package of 4 pens each) / 30 days

References:

1. Wegovy [packet insert]. Novo Nordisk Inc. Plainsboro, NJ 08536. March 2024
2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2020. Updated periodically
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. PMID: 37952131
4. Lingvay I,et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023 Jan;31(1):111-122. doi: 10.1002/oby.23621. Epub 2022 Dec 10. PMID: 36502289; PMCID: PMC10107832.